Myasthenia Gravis News and Research

RSS
Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Muscles that control eye and eyelid movements, facial expression, chewing, talking, and swallowing are often, but not always, involved. The muscles that control breathing and neck and limb movements may also be affected. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. In myasthenia gravis, antibodies produced by the body's own immune system block, alter, or destroy the receptors for acetylcholine. The first noticeable symptoms of myasthenia gravis may be weakness of the eye muscles, difficulty in swallowing, or slurred speech. Symptoms vary in type and severity. Myasthenia gravis is not directly inherited nor is it contagious.
Antibody type prognostic for myasthenia gravis patients

Antibody type prognostic for myasthenia gravis patients

Molecule imitating a virus may trigger inappropriate immune response

Molecule imitating a virus may trigger inappropriate immune response

Scientists discover how Yersinia pestis avoids setting off immune system's early infection-alarm

Scientists discover how Yersinia pestis avoids setting off immune system's early infection-alarm

Study to discover exactly how intravenous immune globulin treatments work

Study to discover exactly how intravenous immune globulin treatments work

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Autoimmune disease myasthenia gravis halted in mice

Autoimmune disease myasthenia gravis halted in mice

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Alexion second quarter net product sales increase to $274.7 million

Alexion second quarter net product sales increase to $274.7 million

Study shows why eating less may be therapeutic for people with neuromuscular disorders

Study shows why eating less may be therapeutic for people with neuromuscular disorders

Communication between brain and muscle cells is short-lived without LRP4 protein

Communication between brain and muscle cells is short-lived without LRP4 protein

FDA approves Levaquin for plague

FDA approves Levaquin for plague

UIC researcher to explore causes of myasthenia gravis

UIC researcher to explore causes of myasthenia gravis

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Intravenous immune globulin effective treatment for GBS, CIDP

Intravenous immune globulin effective treatment for GBS, CIDP

Alexion third quarter total revenues increase to $204.0 million

Alexion third quarter total revenues increase to $204.0 million

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

Anti-malaria drug provides key insight into potential treatments for autoimmune diseases

Anti-malaria drug provides key insight into potential treatments for autoimmune diseases